Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07831122) titled 'Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Canadian Myeloma Research Group
Condition:
Relapsed Refractory Multiple Myeloma (RRMM)
Intervention:
Drug: Belamaf
Biological: Cevostamab
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: December 2026
Target Sample Size: 108
Countries of Recruitment:
Canada
To know more, visit https://clinicaltrials...